封面
市場調查報告書
商品編碼
1541332

2024-2032 年按藥物類別、產品類型、應用、最終用戶和地區分類的促紅血球生成素藥物市場報告

Erythropoietin Drugs Market Report by Drug Class, Product Type, Application, End-User, and Region 2024-2032

出版日期: | 出版商: IMARC | 英文 140 Pages | 商品交期: 2-3個工作天內

價格

IMARC Group年全球促紅血球生成素藥物市場規模達110億美元。貧血和癌症盛行率不斷上升、慢性腎臟病治療應用的增加以及大眾對該藥物潛在影響的認知不斷提高,是推動市場發展的一些關鍵因素。

促紅血球生成素 (EPO) 藥物包括各種藥物,例如促紅血球生成素-α、紅血球生成素-BETA 和達貝泊汀-α,用於治療體內 EPO 缺乏症。它們是使用重組脫氧核糖核酸 (DNA) 技術合成製造的。它們刺激骨髓中紅血球(RBC)的產生並調節體內血紅素的濃度。它們有助於增強耐力、減少疲勞、增加新陳代謝和改善肌肉的癒合過程,同時保持體內紅血球的健康數量。它們用於治療個體之間的各種疾病,例如貧血、末期腎病、人類免疫缺陷病毒(HIV)和血液疾病。除此之外,運動員服用 EPO 藥物可以提高他們的表現和有氧能力,因為它們有助於增加肌肉的氧氣供應。

促紅血球生成素藥物市場趨勢:

目前,由於個體中癌症和神經系統疾病,如自閉症、腦腫瘤、腦性麻痺、癲癇、注意力缺陷障礙(ADD)的盛行率不斷上升,群眾對EPO藥物的需求不斷增加,這是關鍵之一。除此之外,大眾對 EPO 藥物及其有效性的認知不斷提高,這提供了積極的市場前景。此外,世界各地群眾對外科手術介入的需求也在增加。再加上擴大使用 EPO 藥物來減少患者手術後的同種異體輸血,正在推動市場的成長。除此之外,全球範圍內慢性腎病(CKD)病例數量的不斷增加為行業投資者提供了利潤豐厚的成長機會。此外,EPO 藥物提供的各種益處,例如增加紅血球 (RBC) 和減輕疲勞,正在對市場產生積極影響。除此之外,世界各地促紅血球生成素生物相似藥的快速商業化正在推動市場的成長。再加上全球對生物相似藥而非參考藥的日益青睞,正在推動市場的成長。此外,研究機構擴大將 EPO 藥物作為新型治療劑用於眾多研究目的,這正在加強市場的成長。

本報告回答的關鍵問題

  • 全球促紅血球生成素藥物市場有多大? 2024-2032年全球促紅血球生成素藥物市場的預期成長率為何?
  • 推動全球促紅血球生成素藥物市場的關鍵因素是什麼?
  • COVID-19對全球促紅血球生成素藥物市場有何影響?
  • 根據藥物類別,全球促紅血球生成素藥物市場的細分如何?
  • 根據產品類型,全球促紅血球生成素藥物市場的細分如何?
  • 根據應用,全球促紅血球生成素藥物市場的詳細情形如何?
  • 根據最終用戶,全球促紅血球生成素藥物市場的詳細情形如何?
  • 全球促紅血球生成素藥物市場的重點區域有哪些?
  • 全球促紅血球生成素藥物市場的主要參與者/公司有哪些?

目錄

第1章:前言

第 2 章:範圍與方法

  • 研究目的
  • 利害關係人
  • 數據來源
    • 主要來源
    • 二手資料
  • 市場預測
    • 自下而上的方法
    • 自上而下的方法
  • 預測方法

第 3 章:執行摘要

第 4 章:簡介

  • 概述
  • 主要行業趨勢

第 5 章:全球促紅血球生成素藥物市場

  • 市場概況
  • 市場表現
  • COVID-19 的影響
  • 市場預測

第 6 章:市場區隔:依藥物類別

  • 生物製劑
    • 市場趨勢
    • 市場預測
  • 生物相似藥
    • 市場趨勢
    • 市場預測

第 7 章:市場區隔:依產品類型

  • 阿爾法依泊汀
    • 市場趨勢
    • 市場預測
  • BETA-促紅血球生成素
    • 市場趨勢
    • 市場預測
  • 達貝泊汀-阿爾法
    • 市場趨勢
    • 市場預測
  • 其他
    • 市場趨勢
    • 市場預測

第 8 章:市場區隔:按應用

  • 血液學
    • 市場趨勢
    • 市場預測
  • 腎臟疾病
    • 市場趨勢
    • 市場預測
  • 癌症
    • 市場趨勢
    • 市場預測
  • 其他
    • 市場趨勢
    • 市場預測

第 9 章:市場區隔:按最終用戶

  • 醫院
    • 市場趨勢
    • 市場預測
  • 居家護理
    • 市場趨勢
    • 市場預測
  • 專科診所
    • 市場趨勢
    • 市場預測
  • 其他
    • 市場趨勢
    • 市場預測

第 10 章:市場區隔:按地區

  • 北美洲
    • 美國
    • 加拿大
  • 亞太
    • 中國
    • 日本
    • 印度
    • 韓國
    • 澳洲
    • 印尼
    • 其他
  • 歐洲
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙
    • 俄羅斯
    • 其他
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 其他
  • 中東和非洲
    • 市場趨勢
    • 市場細分:按國家/地區
    • 市場預測

第 11 章:SWOT 分析

  • 概述
  • 優勢
  • 弱點
  • 機會
  • 威脅

第 12 章:價值鏈分析

第 13 章:波特五力分析

  • 概述
  • 買家的議價能力
  • 供應商的議價能力
  • 競爭程度
  • 新進入者的威脅
  • 替代品的威脅

第 14 章:價格分析

第15章:競爭格局

  • 市場結構
  • 關鍵參與者
  • 關鍵參與者簡介
    • Amgen Inc.
    • Biocon Limited
    • Dr. Reddy's Laboratories Ltd.
    • F. Hoffmann-La Roche AG
    • Intas Pharmaceuticals Ltd.
    • Johnson & Johnson
    • LG Chem Ltd.
    • Pfizer Inc.
    • Sun Pharmaceutical Industries Limited
    • Teva Pharmaceutical Industries Ltd.
Product Code: SR112024A4270

The global erythropoietin drugs market size reached US$ 11.0 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 17.3 Billion by 2032, exhibiting a growth rate (CAGR) of 5% during 2024-2032. The growing prevalence of anemia and cancer, increasing application in treating chronic kidney disease, and rising awareness among the masses about the potential effects of the drug represent some of the key factors driving the market.

Erythropoietin (EPO) drugs comprise various drugs, such as epoetin-alfa, epoetin-beta, and darbepoetin-alfa, that are consumed to cure EPO deficiency in the body. They are manufactured synthetically using recombinant deoxyribonucleic acid (DNA) technology. They stimulate the production of red blood cells (RBCs) in bone marrow and regulate the concentration of hemoglobin in the body. They assist in enhancing endurance, reducing tiredness, increasing metabolism, and improving the healing process of muscles while maintaining a healthy amount of erythrocytes in the body. They are utilized to treat various diseases, such as anemia, end-stage renal disease, human immunodeficiency virus (HIV), and hematology, among individuals. Besides this, EPO drugs are consumed by athletes to enhance their performance and aerobic capacity, as they benefit in increasing the availability of oxygen to their muscles.

Erythropoietin Drugs Market Trends:

At present, the rising demand for EPO drugs among the masses due to the increasing prevalence of cancer and neurological diseases, such as autism, brain tumors, cerebral palsy, epilepsy, and attention deficit disorder (ADD), among individuals represents one of the key factors supporting the growth of the market. Besides this, the growing awareness among the masses about the EPO drugs and their effectiveness is offering a positive market outlook. Additionally, there is a rise in the need for surgical interventions among the masses around the world. This, coupled with the increasing utilization of EPO drugs to reduce allogeneic blood transfusions after surgical procedures in patients, is propelling the growth of the market. Apart from this, the rising number of chronic kidney disease (CKD) cases among individuals across the globe are offering lucrative growth opportunities to industry investors. Moreover, various benefits offered by EPO drugs, such as increasing red blood cells (RBCs) and reducing fatigue, are positively influencing the market. In addition to this, the rapid commercialization of erythropoietin biosimilars around the world is impelling the growth of the market. This, coupled with the increasing preference for biosimilar drugs rather than reference drugs across the globe, is contributing to the growth of the market. Furthermore, the rising utilization of EPO drugs as novel therapeutic agents in research institutes for numerous research purposes is strengthening the growth of the market.

Key Market Segmentation:

IMARC Group provides an analysis of the key trends in each sub-segment of the global erythropoietin drugs market report, along with forecasts at the global, regional and country level from 2024-2032. Our report has categorized the market based on drug class, product type, application and end user.

Drug Class Insights:

Biologics

Biosimilars

The report has provided a detailed breakup and analysis of the erythropoietin drugs market based on the drug class. This includes biologics and biosimilars. According to the report, biologics represented the largest segment.

Product Type Insights:

Epoetin-alfa

Epoetin-beta

Darbepoetin-alfa

Others

A detailed breakup and analysis of the erythropoietin drugs market based on the product type has also been provided in the report. This includes epoetin-alfa, epoetin-beta, darbepoetin-alfa, and others. According to the report, epoetin-alfa accounted for the largest market share.

Application Insights:

Hematology

Kidney Disorder

Cancer

Others

A detailed breakup and analysis of the erythropoietin drugs market based on the application has also been provided in the report. This includes hematology, kidney disorder, cancer, and others. According to the report, kidney disorder accounted for the largest market share.

End-User Insights:

Hospitals

Homecare

Specialty Clinics

Others

A detailed breakup and analysis of the erythropoietin drugs market based on the end-user has also been provided in the report. This includes hospitals, homecare, specialty clinics, and others. According to the report, hospitals accounted for the largest market share.

Regional Insights:

North America

United States

Canada

Asia-Pacific

China

Japan

India

South Korea

Australia

Indonesia

Others

Europe

Germany

France

United Kingdom

Italy

Spain

Russia

Others

Latin America

Brazil

Mexico

Others

Middle East and Africa

The report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, North America (the United States and Canada) was the largest market for erythropoietin drugs. Some of the factors driving the North America erythropoietin drugs market included the increasing approvals of erythropoietin drugs, various incentives offered by governing agencies for research on chronic diseases, rising prevalence of cancer among individuals, etc.

Competitive Landscape:

The report has also provided a comprehensive analysis of the competitive landscape in the global erythropoietin drugs market. Competitive analysis such as market structure, market share by key players, player positioning, top winning strategies, competitive dashboard, and company evaluation quadrant has been covered in the report. Also, detailed profiles of all major companies have been provided. Some of the companies covered include Amgen Inc., Biocon Limited, Dr. Reddy's Laboratories Ltd., F. Hoffmann-La Roche AG, Intas Pharmaceuticals Ltd., Johnson & Johnson, LG Chem Ltd., Pfizer Inc., Sun Pharmaceutical Industries Limited, Teva Pharmaceutical Industries Ltd., etc. Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.

Key Questions Answered in This Report

  • 1. How big is the global erythropoietin drugs market?
  • 2. What is the expected growth rate of the global erythropoietin drugs market during 2024-2032?
  • 3. What are the key factors driving the global erythropoietin drugs market?
  • 4. What has been the impact of COVID-19 on the global erythropoietin drugs market?
  • 5. What is the breakup of the global erythropoietin drugs market based on the drug class?
  • 6. What is the breakup of the global erythropoietin drugs market based on the product type?
  • 7. What is the breakup of the global erythropoietin drugs market based on the application?
  • 8. What is the breakup of the global erythropoietin drugs market based on the end-user?
  • 9. What are the key regions in the global erythropoietin drugs market?
  • 10. Who are the key players/companies in the global erythropoietin drugs market?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Erythropoietin Drugs Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by Drug Class

  • 6.1 Biologics
    • 6.1.1 Market Trends
    • 6.1.2 Market Forecast
  • 6.2 Biosimilars
    • 6.2.1 Market Trends
    • 6.2.2 Market Forecast

7 Market Breakup by Product Type

  • 7.1 Epoetin-alfa
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2 Epoetin-beta
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast
  • 7.3 Darbepoetin-alfa
    • 7.3.1 Market Trends
    • 7.3.2 Market Forecast
  • 7.4 Others
    • 7.4.1 Market Trends
    • 7.4.2 Market Forecast

8 Market Breakup by Application

  • 8.1 Hematology
    • 8.1.1 Market Trends
    • 8.1.2 Market Forecast
  • 8.2 Kidney Disorder
    • 8.2.1 Market Trends
    • 8.2.2 Market Forecast
  • 8.3 Cancer
    • 8.3.1 Market Trends
    • 8.3.2 Market Forecast
  • 8.4 Others
    • 8.4.1 Market Trends
    • 8.4.2 Market Forecast

9 Market Breakup by End User

  • 9.1 Hospitals
    • 9.1.1 Market Trends
    • 9.1.2 Market Forecast
  • 9.2 Homecare
    • 9.2.1 Market Trends
    • 9.2.2 Market Forecast
  • 9.3 Specialty Clinics
    • 9.3.1 Market Trends
    • 9.3.2 Market Forecast
  • 9.4 Others
    • 9.4.1 Market Trends
    • 9.4.2 Market Forecast

10 Market Breakup by Region

  • 10.1 North America
    • 10.1.1 United States
      • 10.1.1.1 Market Trends
      • 10.1.1.2 Market Forecast
    • 10.1.2 Canada
      • 10.1.2.1 Market Trends
      • 10.1.2.2 Market Forecast
  • 10.2 Asia-Pacific
    • 10.2.1 China
      • 10.2.1.1 Market Trends
      • 10.2.1.2 Market Forecast
    • 10.2.2 Japan
      • 10.2.2.1 Market Trends
      • 10.2.2.2 Market Forecast
    • 10.2.3 India
      • 10.2.3.1 Market Trends
      • 10.2.3.2 Market Forecast
    • 10.2.4 South Korea
      • 10.2.4.1 Market Trends
      • 10.2.4.2 Market Forecast
    • 10.2.5 Australia
      • 10.2.5.1 Market Trends
      • 10.2.5.2 Market Forecast
    • 10.2.6 Indonesia
      • 10.2.6.1 Market Trends
      • 10.2.6.2 Market Forecast
    • 10.2.7 Others
      • 10.2.7.1 Market Trends
      • 10.2.7.2 Market Forecast
  • 10.3 Europe
    • 10.3.1 Germany
      • 10.3.1.1 Market Trends
      • 10.3.1.2 Market Forecast
    • 10.3.2 France
      • 10.3.2.1 Market Trends
      • 10.3.2.2 Market Forecast
    • 10.3.3 United Kingdom
      • 10.3.3.1 Market Trends
      • 10.3.3.2 Market Forecast
    • 10.3.4 Italy
      • 10.3.4.1 Market Trends
      • 10.3.4.2 Market Forecast
    • 10.3.5 Spain
      • 10.3.5.1 Market Trends
      • 10.3.5.2 Market Forecast
    • 10.3.6 Russia
      • 10.3.6.1 Market Trends
      • 10.3.6.2 Market Forecast
    • 10.3.7 Others
      • 10.3.7.1 Market Trends
      • 10.3.7.2 Market Forecast
  • 10.4 Latin America
    • 10.4.1 Brazil
      • 10.4.1.1 Market Trends
      • 10.4.1.2 Market Forecast
    • 10.4.2 Mexico
      • 10.4.2.1 Market Trends
      • 10.4.2.2 Market Forecast
    • 10.4.3 Others
      • 10.4.3.1 Market Trends
      • 10.4.3.2 Market Forecast
  • 10.5 Middle East and Africa
    • 10.5.1 Market Trends
    • 10.5.2 Market Breakup by Country
    • 10.5.3 Market Forecast

11 SWOT Analysis

  • 11.1 Overview
  • 11.2 Strengths
  • 11.3 Weaknesses
  • 11.4 Opportunities
  • 11.5 Threats

12 Value Chain Analysis

13 Porters Five Forces Analysis

  • 13.1 Overview
  • 13.2 Bargaining Power of Buyers
  • 13.3 Bargaining Power of Suppliers
  • 13.4 Degree of Competition
  • 13.5 Threat of New Entrants
  • 13.6 Threat of Substitutes

14 Price Analysis

15 Competitive Landscape

  • 15.1 Market Structure
  • 15.2 Key Players
  • 15.3 Profiles of Key Players
    • 15.3.1 Amgen Inc.
      • 15.3.1.1 Company Overview
      • 15.3.1.2 Product Portfolio
      • 15.3.1.3 Financials
      • 15.3.1.4 SWOT Analysis
    • 15.3.2 Biocon Limited
      • 15.3.2.1 Company Overview
      • 15.3.2.2 Product Portfolio
      • 15.3.2.3 Financials
      • 15.3.2.4 SWOT Analysis
    • 15.3.3 Dr. Reddy's Laboratories Ltd.
      • 15.3.3.1 Company Overview
      • 15.3.3.2 Product Portfolio
      • 15.3.3.3 Financials
      • 15.3.3.4 SWOT Analysis
    • 15.3.4 F. Hoffmann-La Roche AG
      • 15.3.4.1 Company Overview
      • 15.3.4.2 Product Portfolio
      • 15.3.4.3 Financials
    • 15.3.5 Intas Pharmaceuticals Ltd.
      • 15.3.5.1 Company Overview
      • 15.3.5.2 Product Portfolio
    • 15.3.6 Johnson & Johnson
      • 15.3.6.1 Company Overview
      • 15.3.6.2 Product Portfolio
      • 15.3.6.3 Financials
      • 15.3.6.4 SWOT Analysis
    • 15.3.7 LG Chem Ltd.
      • 15.3.7.1 Company Overview
      • 15.3.7.2 Product Portfolio
      • 15.3.7.3 Financials
      • 15.3.7.4 SWOT Analysis
    • 15.3.8 Pfizer Inc.
      • 15.3.8.1 Company Overview
      • 15.3.8.2 Product Portfolio
      • 15.3.8.3 Financials
      • 15.3.8.4 SWOT Analysis
    • 15.3.9 Sun Pharmaceutical Industries Limited
      • 15.3.9.1 Company Overview
      • 15.3.9.2 Product Portfolio
      • 15.3.9.3 Financials
      • 15.3.9.4 SWOT Analysis
    • 15.3.10 Teva Pharmaceutical Industries Ltd.
      • 15.3.10.1 Company Overview
      • 15.3.10.2 Product Portfolio
      • 15.3.10.3 Financials
      • 15.3.10.4 SWOT Analysis

List of Figures

  • Figure 1: Global: Erythropoietin Drugs Market: Major Drivers and Challenges
  • Figure 2: Global: Erythropoietin Drugs Market: Sales Value (in Billion US$), 2018-2023
  • Figure 3: Global: Erythropoietin Drugs Market Forecast: Sales Value (in Billion US$), 2024-2032
  • Figure 4: Global: Erythropoietin Drugs Market: Breakup by Drug Class (in %), 2023
  • Figure 5: Global: Erythropoietin Drugs Market: Breakup by Product Type (in %), 2023
  • Figure 6: Global: Erythropoietin Drugs Market: Breakup by Application (in %), 2023
  • Figure 7: Global: Erythropoietin Drugs Market: Breakup by End User (in %), 2023
  • Figure 8: Global: Erythropoietin Drugs Market: Breakup by Region (in %), 2023
  • Figure 9: Global: Erythropoietin Drugs (Biologics) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 10: Global: Erythropoietin Drugs (Biologics) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 11: Global: Erythropoietin Drugs (Biosimilars) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 12: Global: Erythropoietin Drugs (Biosimilars) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 13: Global: Erythropoietin Drugs (Epoetin-alfa) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 14: Global: Erythropoietin Drugs (Epoetin-alfa) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 15: Global: Erythropoietin Drugs (Epoetin-beta) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 16: Global: Erythropoietin Drugs (Epoetin-beta) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 17: Global: Erythropoietin Drugs (Darbepoetin-alfa) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 18: Global: Erythropoietin Drugs (Darbepoetin-alfa) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 19: Global: Erythropoietin Drugs (Other Product Types) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 20: Global: Erythropoietin Drugs (Other Product Types) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 21: Global: Erythropoietin Drugs (Hematology) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 22: Global: Erythropoietin Drugs (Hematology) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 23: Global: Erythropoietin Drugs (Kidney Disorder) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 24: Global: Erythropoietin Drugs (Kidney Disorder) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 25: Global: Erythropoietin Drugs (Cancer) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 26: Global: Erythropoietin Drugs (Cancer) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 27: Global: Erythropoietin Drugs (Other Applications) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 28: Global: Erythropoietin Drugs (Other Applications) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 29: Global: Erythropoietin Drugs (Hospitals) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 30: Global: Erythropoietin Drugs (Hospitals) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 31: Global: Erythropoietin Drugs (Homecare) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 32: Global: Erythropoietin Drugs (Homecare) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 33: Global: Erythropoietin Drugs (Specialty Clinics) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 34: Global: Erythropoietin Drugs (Specialty Clinics) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 35: Global: Erythropoietin Drugs (Other End Users) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 36: Global: Erythropoietin Drugs (Other End Users) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 37: North America: Erythropoietin Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 38: North America: Erythropoietin Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 39: United States: Erythropoietin Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 40: United States: Erythropoietin Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 41: Canada: Erythropoietin Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 42: Canada: Erythropoietin Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 43: Asia-Pacific: Erythropoietin Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 44: Asia-Pacific: Erythropoietin Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 45: China: Erythropoietin Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 46: China: Erythropoietin Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 47: Japan: Erythropoietin Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 48: Japan: Erythropoietin Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 49: India: Erythropoietin Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 50: India: Erythropoietin Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 51: South Korea: Erythropoietin Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 52: South Korea: Erythropoietin Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 53: Australia: Erythropoietin Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 54: Australia: Erythropoietin Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 55: Indonesia: Erythropoietin Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 56: Indonesia: Erythropoietin Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 57: Others: Erythropoietin Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 58: Others: Erythropoietin Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 59: Europe: Erythropoietin Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 60: Europe: Erythropoietin Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 61: Germany: Erythropoietin Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 62: Germany: Erythropoietin Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 63: France: Erythropoietin Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 64: France: Erythropoietin Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 65: United Kingdom: Erythropoietin Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 66: United Kingdom: Erythropoietin Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 67: Italy: Erythropoietin Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 68: Italy: Erythropoietin Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 69: Spain: Erythropoietin Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 70: Spain: Erythropoietin Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 71: Russia: Erythropoietin Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 72: Russia: Erythropoietin Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 73: Others: Erythropoietin Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 74: Others: Erythropoietin Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 75: Latin America: Erythropoietin Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 76: Latin America: Erythropoietin Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 77: Brazil: Erythropoietin Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 78: Brazil: Erythropoietin Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 79: Mexico: Erythropoietin Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 80: Mexico: Erythropoietin Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 81: Others: Erythropoietin Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 82: Others: Erythropoietin Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 83: Middle East and Africa: Erythropoietin Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 84: Middle East and Africa: Erythropoietin Drugs Market: Breakup by Country (in %), 2023
  • Figure 85: Middle East and Africa: Erythropoietin Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 86: Global: Erythropoietin Drugs Industry: SWOT Analysis
  • Figure 87: Global: Erythropoietin Drugs Industry: Value Chain Analysis
  • Figure 88: Global: Erythropoietin Drugs Industry: Porter's Five Forces Analysis

List of Tables

  • Table 1: Global: Erythropoietin Drugs Market: Key Industry Highlights, 2023 and 2032
  • Table 2: Global: Erythropoietin Drugs Market Forecast: Breakup by Drug Class (in Million US$), 2024-2032
  • Table 3: Global: Erythropoietin Drugs Market Forecast: Breakup by Product Type (in Million US$), 2024-2032
  • Table 4: Global: Erythropoietin Drugs Market Forecast: Breakup by Application (in Million US$), 2024-2032
  • Table 5: Global: Erythropoietin Drugs Market Forecast: Breakup by End User (in Million US$), 2024-2032
  • Table 6: Global: Erythropoietin Drugs Market Forecast: Breakup by Region (in Million US$), 2024-2032
  • Table 7: Global: Erythropoietin Drugs Market: Competitive Structure
  • Table 8: Global: Erythropoietin Drugs Market: Key Players